Secukinumab in psoriasis patients with concurrent psoriatic arthritis: Patient-reported outcomes in the Corrona Psoriasis Registry - 11/08/17
Alice B. Gottlieb, New York Medical College; Bruce Strober, University of Connecticut Health Center; April W. Armstrong, University of Southern California; Jeffrey D. Greenberg, Corrona LLC; Chitra Karki, Corrona LLC; Marc Mason, Corrona LLC; Isabelle Gilloteau, Novartis Pharma AG; Adriana Guana, Novartis Pharmaceuticals Corporation; Mark Lebwohl, Icahn School of Medicine at Mount Sinai
Le texte complet de cet article est disponible en PDF. Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen. |
Vol 76 - N° 6S1
P. AB228 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?